These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 8794311

  • 1. Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals.
    Achour A, Bex F, Hermans P, Burny A, Zagury D.
    J Virol; 1996 Oct; 70(10):6741-50. PubMed ID: 8794311
    [Abstract] [Full Text] [Related]

  • 2. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.
    Belyakov IM, Wyatt LS, Ahlers JD, Earl P, Pendleton CD, Kelsall BL, Strober W, Moss B, Berzofsky JA.
    J Virol; 1998 Oct; 72(10):8264-72. PubMed ID: 9733870
    [Abstract] [Full Text] [Related]

  • 3. Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.
    Kiszka I, Kmieciak D, Gzyl J, Naito T, Bolesta E, Sieron A, Singh SP, Srinivasan A, Trinchieri G, Kaneko Y, Kozbor D.
    J Virol; 2002 May; 76(9):4222-32. PubMed ID: 11932387
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope.
    Achour A, Picard O, Mbika JP, Willer A, Snart R, Bizzini B, Carelli C, Burny A, Zagury D.
    Vaccine; 1993 May; 11(7):609-701. PubMed ID: 7688170
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18IIIB peptide in an HLA-A11-immunized individual.
    Achour A, Lemhammedi S, Picard O, M'Bika JP, Zagury JF, Moukrim Z, Willer A, Beix F, Burny A, Zagury D.
    AIDS Res Hum Retroviruses; 1994 Jan; 10(1):19-25. PubMed ID: 8179960
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G.
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [Abstract] [Full Text] [Related]

  • 13. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
    Wagner R, Modrow S, Böltz T, Fliessbach H, Niedrig M, von Brunn A, Wolf H.
    Arch Virol; 1992 Feb; 127(1-4):139-52. PubMed ID: 1456889
    [Abstract] [Full Text] [Related]

  • 14. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW.
    AIDS Res Hum Retroviruses; 1998 Jul 20; 14(11):925-37. PubMed ID: 9686639
    [Abstract] [Full Text] [Related]

  • 15. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
    Bergmann C, Stohlmann SA, McMillan M.
    Eur J Immunol; 1993 Nov 20; 23(11):2777-81. PubMed ID: 7693478
    [Abstract] [Full Text] [Related]

  • 16. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant.
    Takahashi H, Nakagawa Y, Pendleton CD, Houghten RA, Yokomuro K, Germain RN, Berzofsky JA.
    Science; 1992 Jan 17; 255(5042):333-6. PubMed ID: 1372448
    [Abstract] [Full Text] [Related]

  • 17. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160.
    Takahashi H, Merli S, Putney SD, Houghten R, Moss B, Germain RN, Berzofsky JA.
    Science; 1989 Oct 06; 246(4926):118-21. PubMed ID: 2789433
    [Abstract] [Full Text] [Related]

  • 18. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, Stablein DM, Deers M, Corey L, Greenberg ML, Schwartz DH, Montefiori DC.
    AIDS Res Hum Retroviruses; 2000 Dec 10; 16(18):2019-35. PubMed ID: 11153085
    [Abstract] [Full Text] [Related]

  • 19. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, Fisher G.
    J Clin Invest; 1993 May 10; 91(5):1987-96. PubMed ID: 7683694
    [Abstract] [Full Text] [Related]

  • 20. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.
    McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, Schnell MJ.
    J Virol; 2001 May 10; 75(9):4430-4. PubMed ID: 11287595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.